Navigation Links
Vaccinex Antibody Licensed to GlaxoSmithKline
Date:2/15/2008

ROCHESTER, N.Y., Feb. 15 /PRNewswire/ -- EUSA Pharma (Oxford, UK), a Vaccinex collaboration partner, has announced that it has licensed OP-R003, a human anti-interleukin-6 antibody discovered by Vaccinex, to GlaxoSmithKline.

According to the terms of the product license, GSK will pay an up-front license fee, development milestones, and royalties on product sales to acquire the exclusive world-wide rights to develop and commercialize OP-R003 for the treatment of rheumatoid arthritis and other disease indications. Vaccinex will share 50% of fees, payments and royalties. The antibody was discovered by Vaccinex utilizing its ActivMAb(R) antibody discovery technology and first licensed for co-development by EUSA Pharma (formerly OPi SA).

"We are pleased that our collaboration in the discovery and co-development of OP-R003 has attracted such a world-class partner as GSK. Together with previously announced antibody partnerships with Biocon, Ltd. and Teva Pharmaceutical, this transaction further validates the quality of human antibodies selected with Vaccinex's ActivMAb(R) antibody discovery technology," remarked Dr. Maurice Zauderer, Vaccinex's President and CEO.

Commenting on the acquisition, Brian McVeigh, GSK's Worldwide Business Development Director of M&A Strategy and Transactions, said, "Interleukin-6 is increasingly recognized as an important biological target in a range of diseases, and consequently OP-R003 has great potential to meet a number of unmet medical needs."

About Vaccinex

Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies and other biologics to treat a variety of serious illnesses, including autoimmune disease, inflammation, multiple sclerosis, and cancer. The company's patented ActivMAb(R) technology allows for the direct selection of high affinity, fully human monoclonal antibodies that would be difficult or impossible to identify using other systems. Vaccinex, on its own or with its partners, has advanced several antibodies from discovery and lead validation into IND-directed pre-clinical drug development. The company is headquartered in Rochester, NY, USA. For more information, please visit http://www.vaccinex.com.

Press Contact

Raymond E. Watkins, Vice President of Operations & Officer

Vaccinex, Inc.

+1.585.271.2700 Ext. 105

E-mail: rwatkins@vaccinex.com


'/>"/>
SOURCE Vaccinex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vaccinex, Inc. Announces Award of Key Patent in Europe for its Antibody Discovery Technology (ActivMab(R))
2. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
3. Human Genome Sciences and Xencor Announce Antibody Collaboration
4. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
5. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
6. Roche Files IND for Second Genmab Antibody
7. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
8. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
9. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
10. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
11. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... N.C. (PRWEB) , ... October 11, 2017 , ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, ... ( ASTER Labs ), Inc. has been selected for membership in ARCS ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
Breaking Biology Technology:
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
Breaking Biology News(10 mins):